| scholarly article | Q13442814 |
| P50 | author | Alexander Eggermont | Q28317101 |
| Virginia Ferraresi | Q57061632 | ||
| Jedd D. Wolchok | Q88137705 | ||
| Paolo Antonio Ascierto | Q89457677 | ||
| F Stephen Hodi | Q90321337 | ||
| Stefan Suciu | Q99568574 | ||
| Axel Hauschild | Q32649861 | ||
| Reinhard Dummer | Q32650033 | ||
| Michele Maio | Q37391116 | ||
| Jean-Jacques Grob | Q40580858 | ||
| Caroline Robert | Q41784107 | ||
| Lars Bastholt | Q56849196 | ||
| P2093 | author name string | Vanna Chiarion-Sileni | |
| Jeffrey S Weber | |||
| Jessica C Hassel | |||
| Luc Thomas | |||
| Omid Hamid | |||
| Céleste Lebbé | |||
| Alessandro Testori | |||
| Michael Smylie | |||
| Laurent Mortier | |||
| Henrik Schmidt | |||
| Veerle de Pril | |||
| Saad Tahir | |||
| Jon M Richards | |||
| Corina Taitt | |||
| Gaetan de Schaetzen | |||
| P2860 | cites work | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| Cutaneous melanoma | Q56897036 | ||
| Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma | Q87371992 | ||
| Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial | Q29396936 | ||
| Final version of 2009 AJCC melanoma staging and classification | Q29614803 | ||
| Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma | Q30890582 | ||
| Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial | Q33224408 | ||
| Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes | Q33394167 | ||
| Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria | Q33881765 | ||
| Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases | Q34315676 | ||
| Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial | Q34594112 | ||
| Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study | Q34614776 | ||
| The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients | Q35001487 | ||
| Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensi | Q35899104 | ||
| Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. | Q37697383 | ||
| Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? | Q37974805 | ||
| Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial | Q38404655 | ||
| Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. | Q40671706 | ||
| Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. | Q44280829 | ||
| Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials | Q47678860 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ipilimumab | Q2459042 |
| P304 | page(s) | 1845-1855 | |
| P577 | publication date | 2016-10-07 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy | |
| P478 | volume | 375 |
| Q57288782 | Q57288782 |
| Q57288798 | Q57288798 |
| Q61813839 | A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer |
| Q92180153 | A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden |
| Q52822549 | A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients. |
| Q60644218 | Acral Melanoma: A Patient's Experience and Physician's Commentary |
| Q46518214 | Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. |
| Q51052594 | Adjuvant Therapy for Melanoma. |
| Q57569466 | Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial |
| Q40349062 | Adjuvant ipilimumab for stage III melanoma: the patient voice. |
| Q90210304 | Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? |
| Q94952253 | Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial |
| Q99603990 | Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial |
| Q98946920 | Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects |
| Q47397616 | Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success? |
| Q92220435 | Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review |
| Q48224477 | Adjuvant therapy with low-dose interferon-beta for stage II and III melanoma: results of a retrospective analysis. |
| Q52686844 | Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. |
| Q47375181 | Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. |
| Q92881768 | Advances in cancer immunotherapy 2019 - latest trends |
| Q92052685 | Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance |
| Q93136489 | An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma |
| Q91558300 | An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma |
| Q91739924 | An update on adjuvant systemic therapies in melanoma |
| Q55206910 | An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. |
| Q50573517 | Annual Congress of the European Society for Medical Oncology (ESMO): Copenhagen, Denmark; 7-11 October 2016. |
| Q92021395 | Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer |
| Q92702383 | Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update |
| Q92373122 | Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial |
| Q92920997 | Astragaloside III Enhances Anti-Tumor Response of NK Cells by Elevating NKG2D and IFN-γ |
| Q52615452 | Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. |
| Q37573430 | Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7-10 October 2016. |
| Q57061755 | Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study |
| Q56891027 | CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients |
| Q60489257 | Cancer immunoediting and resistance to T cell-based immunotherapy |
| Q49260236 | Cancer vaccine: learning lessons from immune checkpoint inhibitors |
| Q92704205 | Cancérologie cutanée et dermatite atopique |
| Q90255944 | Cardiorenal complications of immune checkpoint inhibitors |
| Q52592605 | Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management. |
| Q39144916 | Cardiovascular Toxicities Associated with Cancer Immunotherapies |
| Q50231313 | Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies |
| Q58080646 | Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma |
| Q89538337 | Changes and Clinical Significance of Detailed Peripheral Lymphocyte Subsets in Evaluating the Immunity for Cancer Patients |
| Q92490032 | Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis |
| Q47304240 | Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract |
| Q64110235 | Checkpoint Inhibitors |
| Q89532702 | Checkpoint inhibitor immunotherapy in kidney cancer |
| Q42343743 | Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future? |
| Q48522100 | Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. |
| Q90642530 | Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study |
| Q61798878 | Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury |
| Q90468497 | Clinical characterization of colitis arising from anti-PD-1 based therapy |
| Q57143867 | Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy |
| Q38730176 | Clinical prognostic markers in stage IIIC melanoma |
| Q49342746 | ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors |
| Q89726549 | Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma |
| Q91732530 | Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control |
| Q59125545 | Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV |
| Q60922811 | Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle |
| Q64910760 | Combination of CTLA-4 and PD-1 blockers for treatment of cancer. |
| Q38679418 | Combining radiotherapy with immunotherapy: the past, the present and the future |
| Q92718641 | Conclusions from quality of life studies in patients with resected high-risk melanoma: one part of the full story |
| Q92206685 | Considering adjuvant therapy for stage II melanoma |
| Q59361035 | Contemporary Approaches to In-Transit Melanoma |
| Q55022893 | Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. |
| Q99400989 | Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France |
| Q89860520 | Current Advances in the Treatment of BRAF-Mutant Melanoma |
| Q93039741 | Current Development of Monoclonal Antibodies in Cancer Therapy |
| Q37629874 | Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy |
| Q49357054 | Current aspects in the prognosis of advanced melanoma |
| Q47326952 | De-novo and acquired resistance to immune checkpoint targeting. |
| Q92920605 | Dehydrocorydaline inhibits cell proliferation, migration and invasion via suppressing MEK1/2-ERK1/2 cascade in melanoma |
| Q57486475 | Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time |
| Q57279925 | Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes |
| Q47767814 | Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy. |
| Q64970972 | Dissecting the role of RNA modification regulatory proteins in melanoma. |
| Q93015595 | E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma |
| Q92106711 | Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy |
| Q57167691 | Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan |
| Q91978643 | Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer |
| Q42067472 | Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers. |
| Q38902180 | Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma |
| Q64272058 | Emerging Nano-/Microapproaches for Cancer Immunotherapy |
| Q48289680 | Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. |
| Q90093477 | Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma |
| Q37462866 | European Society for Medical Oncology 2016 Congress |
| Q47738907 | Evaluation of the eighth American Joint Committee on Cancer staging system for malignant melanoma of the skin |
| Q47182822 | Expression signatures of early-stage and advanced medaka melanomas |
| Q91920720 | External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma |
| Q47138521 | Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation |
| Q90416214 | Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives |
| Q47241481 | Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer |
| Q57095063 | Has the melanoma information tsunami become a maelstrom? |
| Q64030269 | Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy |
| Q52686500 | Higher than reported adolescent and young adult clinical trial enrollment during the "Golden Age" of melanoma clinical trials. |
| Q47217258 | Highlights of the season 2016–2017 by the Spanish Melanoma Group (GEM). |
| Q91565220 | Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy |
| Q92499927 | Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial |
| Q55409972 | Identifying and managing the adverse effects of immune checkpoint blockade. |
| Q39313889 | Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy |
| Q45959320 | Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. |
| Q50021106 | Immune Checkpoint Blockade: The New Frontier in Cancer Treatment |
| Q56890746 | Immune Checkpoint Inhibitor Toxicity |
| Q39328076 | Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management |
| Q57490955 | Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease |
| Q47138765 | Immune Checkpoint Inhibitors in Melanoma and HIV Infection |
| Q53068034 | Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. |
| Q90319842 | Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings |
| Q90569873 | Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls |
| Q91786172 | Immune-Related Adverse Events: A Case-Based Approach |
| Q55418935 | Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. |
| Q91905605 | Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis |
| Q46694815 | Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review |
| Q39332694 | Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review |
| Q38632924 | Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection |
| Q38738652 | Immunotherapy for gastric cancers: emerging role and future perspectives |
| Q50166276 | Immunotherapy in managing metastatic melanoma: which treatment when? |
| Q56892854 | Immunotherapy of melanoma |
| Q50203119 | Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life? |
| Q50010320 | Impact of genomics on the surgical management of melanoma. |
| Q60923000 | Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis |
| Q55438940 | Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. |
| Q92805598 | Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data |
| Q47986213 | Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives |
| Q57280953 | Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis |
| Q92306383 | Integration of radiotherapy and immunotherapy for treatment of oligometastases |
| Q58747512 | Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience |
| Q89766256 | Intratumoral immunotherapy for early stage solid tumors |
| Q47281370 | Intratumoral immunotherapy: using the tumor as the remedy |
| Q50057704 | Ipilimumab induced digital vasculitis |
| Q50142484 | Ist eine komplette Lymphknotendissektion beim malignen Melanom mit positivem Sentinel notwendig? |
| Q91788117 | Learning from clinical trials of neoadjuvant checkpoint blockade |
| Q88683585 | Less cholesterol means better tumor killing for cytotoxic T9 cells |
| Q50088009 | Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma. |
| Q47726847 | Liquid biomarkers in melanoma: detection and discovery. |
| Q98945175 | Liver biopsy findings in patients on immune checkpoint inhibitors |
| Q55619003 | Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. |
| Q58599454 | Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach? |
| Q99568575 | Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial |
| Q57803583 | Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma |
| Q64124167 | MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial |
| Q64288049 | Making adjuvant therapy decisions with uncertain data |
| Q40113867 | Malignant melanoma : Current status |
| Q50205173 | Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q47102520 | Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group |
| Q93000881 | Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies |
| Q91610930 | Melanoma |
| Q90745277 | Melanoma Radiological Surveillance: A Review of Current Evidence and Clinical Challenges |
| Q88142272 | Melanoma and Immune Checkpoint Inhibitors |
| Q49577605 | Melanoma in 2017: Moving treatments earlier to move further forwards |
| Q100762155 | Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis |
| Q47803820 | Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual |
| Q47227422 | Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells |
| Q51104725 | Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab. |
| Q59497151 | Metastatic melanoma patients' sensitivity to ipilimumab cannot be predicted by tumor characteristics |
| Q47378156 | Mitotic Rate is Associated with Positive Lymph Nodes in Thin Melanomas. |
| Q90512934 | Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection |
| Q92388464 | Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases |
| Q91612752 | Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient |
| Q57295552 | Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma |
| Q47844531 | Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial |
| Q52707591 | Neoadjuvant therapy in melanoma: the next step? |
| Q92485631 | Neoadjuvant therapy of locally/regionally advanced melanoma |
| Q94355088 | Neoadjuvant treatment for malignant and metastatic cutaneous melanoma |
| Q57295546 | Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma |
| Q56889672 | Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases |
| Q50215033 | Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management |
| Q92621529 | New paradigm for stage III melanoma: from surgery to adjuvant treatment |
| Q42315574 | News from the melanoma sessions of the European Cancer Congress 2017. |
| Q39108144 | Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics |
| Q92363011 | Novel Delivery Systems for Checkpoint Inhibitors |
| Q64883379 | Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome. |
| Q95282151 | Oncologic Emergencies: Immune-Based Cancer Therapies and Complications |
| Q47669815 | Optimal extent of completion lymphadenectomy for patients with melanoma and a positive sentinel node in the groin |
| Q87709074 | Optimum dosing of ipilimumab in melanoma: too little, too late? |
| Q92718636 | Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial |
| Q92580190 | Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma |
| Q53461340 | Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. |
| Q48222490 | Perioperative BRAF inhibitors in locally advanced stage III melanoma. |
| Q64988012 | Personalized cancer neoantigen vaccines come of age. |
| Q42375254 | Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. |
| Q90382728 | Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy) |
| Q92086166 | Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy) |
| Q55029444 | Perspectives on the clinical development of immunotherapy in prostate cancer. |
| Q33741471 | Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma |
| Q48705388 | Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Resear |
| Q90728798 | Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma |
| Q92297174 | Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients |
| Q37742635 | Precision medicine driven by cancer systems biology |
| Q92152629 | Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA |
| Q47724234 | Prediction of Non-sentinel Node Status in Patients with Melanoma and Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup (IMI) Study. |
| Q42290505 | Prediction of Response in Melanoma Therapy by Systemic Inflammatory Response - One Size Fits Not All. |
| Q41701241 | Predictors of responses to immune checkpoint blockade in advanced melanoma |
| Q89450684 | Preface: More than two decades of modern tumor immunology |
| Q91284516 | Preface: More than two decades of modern tumor immunology |
| Q95591987 | Preface: More than two decades of modern tumor immunology |
| Q92381909 | Preferences of Canadian patients and physicians for adjuvant treatments for melanoma |
| Q93255453 | Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanoma |
| Q92789482 | Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases |
| Q92124242 | Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy |
| Q38832053 | Prognostic risk factors of first recurrence in patients with primary stages I-II cutaneous malignant melanoma - from the population-based Swedish melanoma register |
| Q40494079 | Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. |
| Q92002182 | Prospective cohort study of ultrasound surveillance of regional lymph nodes in patients with intermediate-risk cutaneous melanoma |
| Q92869017 | Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma |
| Q52691700 | Quantitative Analysis of Immune Infiltrates in Primary Melanoma. |
| Q96302844 | RAS-targeted therapies: is the undruggable drugged? |
| Q55491553 | Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. |
| Q50025731 | Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON). |
| Q47681371 | Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barré syndrome |
| Q90529204 | Rational combination of cancer immunotherapy in melanoma |
| Q39255886 | Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy |
| Q59800887 | Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results |
| Q64059605 | Recent advances in triple negative breast cancer: the immunotherapy era |
| Q47784321 | Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. |
| Q41849636 | Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies |
| Q90242060 | Rheumatic complications in cancer patients treated with immune checkpoint inhibitors |
| Q57143926 | Rheumatic immune-related adverse events from cancer immunotherapy |
| Q91781720 | Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy |
| Q48342771 | SEOM clinical guideline for the management of malignant melanoma (2017). |
| Q55076131 | Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome. |
| Q38784286 | Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study |
| Q58092607 | Sentinel Lymph Node Biopsy: Past and Present Implications for the Management of Cutaneous Melanoma with Nodal Metastasis |
| Q88093912 | Sentinel lymph node biopsy in cutaneous head and neck melanoma |
| Q48273215 | Sentinel lymph node biopsy versus observation in thick melanoma: A multicenter propensity score matching study. |
| Q54936318 | Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. |
| Q41952060 | Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology |
| Q47131425 | Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab |
| Q42343618 | Spotlight on landmark oncology trials: the latest evidence and novel trial designs. |
| Q51741753 | Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. |
| Q38749639 | Standard of care in immunotherapy trials: Challenges and considerations. |
| Q47278600 | Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review |
| Q90697071 | Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline |
| Q38653012 | Systemic therapy following metastasectomy for renal cell carcinoma: Using insights from other clinical settings to address unanswered questions |
| Q91522807 | T cell-engaging therapies - BiTEs and beyond |
| Q61810153 | Targeted Therapy and Immunotherapy for Melanoma in Japan |
| Q55235076 | Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. |
| Q57178624 | The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management |
| Q93039772 | The Era of Checkpoint Inhibition: Lessons Learned from Melanoma |
| Q91994675 | The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019 |
| Q92888273 | The Systemic Treatment of Melanoma |
| Q64256609 | The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer |
| Q52686846 | The brim of uncertainty in adjuvant treatment of melanoma. |
| Q38638847 | The colorectal cancer immune microenvironment and approach to immunotherapies. |
| Q39382600 | The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma |
| Q89163202 | The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care |
| Q64264660 | The evolving role of immuno-oncology for the treatment of head and neck cancer |
| Q92176245 | The extent of surgery for stage III melanoma: how much is appropriate? |
| Q64987811 | The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018. |
| Q50079737 | The link between calcitriol and anticancer immunotherapy: vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade |
| Q92580177 | The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma |
| Q88924838 | The new era of adjuvant therapies for melanoma |
| Q47735641 | The role of nivolumab in melanoma |
| Q47138418 | The sexist behaviour of immune checkpoint inhibitors in cancer therapy? |
| Q47906372 | Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma |
| Q91868405 | Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome |
| Q91884312 | Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population-based study |
| Q47141380 | Tregs: Where We Are and What Comes Next? |
| Q47393365 | Trial watch: Immune checkpoint blockers for cancer therapy |
| Q47999192 | Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. |
| Q30846001 | Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. |
| Q92835077 | Unlocking the therapeutic potential of primary tumor-draining lymph nodes |
| Q37739214 | Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer |
| Q56890934 | Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs |
| Q64954806 | Updates in adjuvant systemic therapy for melanoma. |
| Q64122915 | Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures |
| Q94526286 | Use of immuno-oncology in melanoma |
| Q91912719 | Vulvar malignancies: an interdisciplinary perspective |
| Q49294667 | What is changing in the adjuvant treatment of melanoma? |
| Q56894089 | What is new in melanoma after European Cancer Congress 2017? |
| Q39441123 | When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the 'Australian guidelines for the management of cutaneous melanoma'. |
| Q90664412 | [Sentinel node biopsy and lymph node dissection in the era of new systemic therapies for malignant melanoma] |
| Q52801913 | β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas. |
Search more.